CMV reaction
| Characteristic . | Value . |
|---|---|
| No. of at-risk patients with CMV viremia*(%) | 27/53 (51) |
| No. of low-risk† patients with viremia (%) | 12/23 (52) |
| No. of high-risk‡ patients with viremia (%) | 15/30 (50) |
| Median days to viremia (range) | 41 (9-98) |
| Median weeks to clear viremia | 3 |
| No. of at-risk patients with suspected CMV disease (%) | 4/53 (7.5) |
| Proven colitis | 1 |
| Probable pneumonitis | 1 |
| Possible pneumonitis | 2 |
| Characteristic . | Value . |
|---|---|
| No. of at-risk patients with CMV viremia*(%) | 27/53 (51) |
| No. of low-risk† patients with viremia (%) | 12/23 (52) |
| No. of high-risk‡ patients with viremia (%) | 15/30 (50) |
| Median days to viremia (range) | 41 (9-98) |
| Median weeks to clear viremia | 3 |
| No. of at-risk patients with suspected CMV disease (%) | 4/53 (7.5) |
| Proven colitis | 1 |
| Probable pneumonitis | 1 |
| Possible pneumonitis | 2 |
CMV viremia defined as >150 copies/mL on PCR.
CMV low-risk defined as both donor and recipient CMV-positive during pre-BMT evaluation and includes 1 patient who was neither donor nor recipient positive but had CMV viremia.
CMV high-risk defined as either donor or recipient CMV-positive during pre-BMT evaluation.